Preços de transferência e a indústria farmacêutica no Brasil

Detalhes bibliográficos
Ano de defesa: 2009
Autor(a) principal: Silva Júnior, Johnston Viana da
Orientador(a): Santos, Roberto Fernandes dos
Banca de defesa: Não Informado pela instituição
Tipo de documento: Dissertação
Tipo de acesso: Acesso aberto
Idioma: por
Instituição de defesa: Pontifícia Universidade Católica de São Paulo
Programa de Pós-Graduação: Programa de Estudos Pós-Graduados em Ciências Contábeis e Atuariais
Departamento: Ciências Cont. Atuariais
País: BR
Palavras-chave em Português:
Palavras-chave em Inglês:
Área do conhecimento CNPq:
Link de acesso: https://tede2.pucsp.br/handle/handle/1728
Resumo: Transfer pricing is the result of globalization. The growth of international commerce has made the governments improve the price control over sales and purchase of goods, services and rights of multinational companies in different fiscal areas. The fiscal authorities seek to avoid losing fiscal income when the profit is transferred between multinational companies and these companies seek to decrease their tax load. OECD (Organization For Economic Co-Operation And Development), that brings together the thirty most industrialized open market economies, released between 1995 to 1997 guidelines about transfer pricing according to Arm s length principle and recommended the adherence of the signing countries. Brazil is not a participant of OECD, but, following the globalization trend of the economy, it issued the Law 9.430/96 about transfer pricing control. Transfer pricing control is so important and complex for the fiscal authorities as it is for tax managers of multinational companies. The importance and complexity of the transfer pricing control is stressed when it is applied to import of the Brazilian pharmaceutical companies that operate in the market under economical regulation. The regulating authorities intervene in the Brazilian pharmaceutical market because they seek socially desirable results, controlling the selling prices of medicines. The goal of this dissertation is to show whether the current transfer pricing methods are the most adequate in the present economic regulation of the pharmaceutical market. Therefore, we consider simulated imports of pharmaceutical products in the price controlled environments in the scenarios: according to Arm s Length principle, controlled and non-controlled selling prices, international raw material and supplies upgrading of prices, changes in the place of the productive process and exchange rate. This study shows the results of the multinational company operation can be overloaded because of tax upgrades using the transfer pricing methods when importing pharmaceutical products. Several litigations have happened between pharmaceutical segment taxpayers and fiscal authorities related to the current rules of transfer pricing. Facing the present regulating levels in the Brazilian pharmaceutical market, we emphasize that Advance Pricing Agreements can turn out to be a proper alternative to minimize these conflicts